rotation.to
Following this device: dark.
Free account
rotation.to
Sign in / Request free access
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

Who

William J.L. Rieflin

Director

Company insider

Files Form 4 as: Director, Lycia Therapeutics; Director, Lyell Immunopharma; Director, RAPT Therapeutics; Executive Chairman, Ngm Biopharmaceuticals; President, Xenoport; Director, Anacor Pharmaceuticals.

Every Form 4 they filed

In numbers

Trades disclosed
131
Buys
7
Sells
1
Bought
$409K
Sold
$93K
Companies
6
Companies where not an officer
4
First trade
16 Nov 2005
Last trade
22 Oct 2026
Last filed
26 Oct 2026

Companies traded

Where they are an officer
Ngm BiopharmaceuticalsDirector, Officer · last 5 Apr 20240 buys · 0 sells
XenoportDirector, Officer · last 5 Jul 20165 buys · 1 sell
Everywhere else they filed: board seats, 10% stakes, other companies
LYCA Lycia TherapeuticsDirector · Biotechnology · last 22 Oct 20260 buys · 0 sells
LYEL Lyell ImmunopharmaDirector · Biotechnology · last 10 Jun 20260 buys · 0 sells
RAPT TherapeuticsDirector · last 23 May 20242 buys · 0 sells
Anacor PharmaceuticalsDirector · last 24 Jun 20160 buys · 0 sells

Activity over time

1 Nov 2024 – 1 Oct 2026
101Nov 24May 25Nov 25Apr 26Oct 26

Buys above the line, sells below, each month.

Every trade

TradedCompanyWhatAmount
22 Oct 2026filed 26 Oct 2026LYCA Lycia Therapeuticsoption or derivative · BiotechnologySEC FORM 4 Code A—20,000 at $0.00filing
11 Aug 2026filed 26 Oct 2026LYCA Lycia Therapeuticsoption or derivative · BiotechnologySEC FORM 4 Code A—24,840 at $0.00filing
10 Jun 2026filed 12 Jun 2026LYEL Lyell Immunopharmaoption or derivative · BiotechnologySEC FORM 4 Code A—9,250 at $0.00filing
10 Jun 2026filed 12 Jun 2026LYEL Lyell Immunopharmaoption or derivative · BiotechnologySEC FORM 4 Code A—9,250 at $0.00filing
15 May 2025filed 19 May 2025LYEL Lyell Immunopharmaoption or derivative · BiotechnologySEC FORM 4 Code A—130,000 at $0.00filing
14 Jun 2024filed 17 Jun 2024LYEL Lyell Immunopharmaoption or derivative · BiotechnologySEC FORM 4 Code A—130,000 at $0.00filing
23 May 2024filed 23 May 2024RAPT Therapeuticsoption or derivativeSEC FORM 4 Code A—36,490 at $0.00filing
5 Apr 2024filed 8 Apr 2024Ngm Biopharmaceuticalsoption or derivativeSEC FORM 4 Code D—78,407filing
5 Apr 2024filed 8 Apr 2024Ngm Biopharmaceuticalsoption or derivativeSEC FORM 4 Code D—80,000filing
5 Apr 2024filed 8 Apr 2024Ngm Biopharmaceuticalsoption or derivativeSEC FORM 4 Code D—80,000filing
5 Apr 2024filed 8 Apr 2024Ngm Biopharmaceuticalsoption or derivativeSEC FORM 4 Code D—75,000filing
5 Apr 2024filed 8 Apr 2024Ngm Biopharmaceuticalsoption or derivativeSEC FORM 4 Code D—50,000filing
5 Apr 2024filed 8 Apr 2024Ngm Biopharmaceuticalsoption or derivativeSEC FORM 4 Code D—225,000filing
5 Apr 2024filed 8 Apr 2024Ngm BiopharmaceuticalsSEC FORM 4 Code U—5,172filing
5 Apr 2024filed 8 Apr 2024Ngm BiopharmaceuticalsSEC FORM 4 Code U—2,769,168filing
28 Mar 2024filed 1 Apr 2024RAPT Therapeuticsoption or derivativeSEC FORM 4 Code A$90K11,871 at $7.58filing
8 Sep 2023filed 8 Sep 2023LYEL Lyell Immunopharmaoption or derivative · BiotechnologySEC FORM 4 Code A—55,000 at $0.00filing
16 Jun 2023filed 20 Jun 2023LYEL Lyell Immunopharmaoption or derivative · BiotechnologySEC FORM 4 Code A—65,000 at $0.00filing
24 May 2023filed 25 May 2023RAPT Therapeuticsoption or derivativeSEC FORM 4 Code A—12,940 at $0.00filing
10 May 2023filed 12 May 2023Ngm Biopharmaceuticalsoption or derivativeSEC FORM 4 Code A—78,407 at $0.00filing

News

No headline names them, or the companies they trade most, lately.

Sectors

Not placed8

Buys in green, sells in red, by the company’s sector.

Related people

Nobody else traded the same names lately.